

Valentina Nardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11443302/publications.pdf>

Version: 2024-02-01

88
papers

3,531
citations

218677

26
h-index

144013

57
g-index

88
all docs

88
docs citations

88
times ranked

6245
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. <i>Nature</i> , 2009, 460, 259-263.	27.8	938
2	Mechanisms and implications of imatinib resistance mutations in BCR-ABL. <i>Current Opinion in Hematology</i> , 2004, 11, 35-43.	2.5	170
3	Merkel Cell Carcinoma: 30-Year Experience from a Single Institution. <i>Annals of Surgical Oncology</i> , 2013, 20, 1365-1373.	1.5	117
4	Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. <i>FASEB Journal</i> , 2020, 34, 13877-13884.	0.5	117
5	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz094.	2.9	114
6	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	3.7	112
7	Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment. <i>Clinical Cancer Research</i> , 2013, 19, 480-490.	7.0	105
8	Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. <i>Cancer Discovery</i> , 2015, 5, 1058-1071.	9.4	105
9	Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9244-9249.	7.1	104
10	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 81-112.	4.9	102
11	Activation of PI3K Signaling in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1227-1236.	7.0	97
12	Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. <i>Modern Pathology</i> , 2017, 30, 1489-1503.	5.5	93
13	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. <i>Cancer</i> , 2017, 123, 1979-1988.	4.1	92
14	Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms. <i>Journal of Clinical Oncology</i> , 2012, 30, 2340-2347.	1.6	89
15	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018, 9, 2024.	12.8	80
16	A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. <i>Cell Reports</i> , 2017, 21, 784-797.	6.4	65
17	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018, 131, 2816-2825.	1.4	64
18	Syphilis of the Aerodigestive Tract. <i>American Journal of Surgical Pathology</i> , 2018, 42, 472-478.	3.7	55

#	ARTICLE	IF	CITATIONS
19	Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. <i>Modern Pathology</i> , 2020, 33, 560-565.	5.5	46
20	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. <i>Modern Pathology</i> , 2015, 28, 552-563.	5.5	42
21	EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. <i>Modern Pathology</i> , 2016, 29, 1200-1211.	5.5	38
22	A Nanopore Sequencing-Based Assay for Rapid Detection of Gene Fusions. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 58-69.	2.8	34
23	Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. <i>Haematologica</i> , 2021, 106, 555-564.	3.5	34
24	GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 1720-1727.	5.5	33
25	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 661-668.	2.8	31
26	Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 235-243.	3.7	29
27	JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. <i>American Journal of Surgical Pathology</i> , 2021, 45, 895-904.	3.7	29
28	Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 3136-3140.	5.2	28
29	Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. <i>Human Pathology</i> , 2019, 93, 65-73.	2.0	27
30	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385.	5.5	25
31	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	1.2	25
32	Laboratory testing in <i>BCR-ABL1</i> -like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 971-977.	4.1	24
33	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. <i>Human Pathology</i> , 2019, 86, 1-11.	2.0	24
34	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A and VIM-KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.	5.5	24
35	Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. <i>Blood Advances</i> , 2020, 4, 106-111.	5.2	23
36	MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections. <i>Frontiers in Endocrinology</i> , 2020, 11, 480.	3.5	22

#	ARTICLE	IF	CITATIONS
37	A screen to identify drug resistant variants to target-directed anti-cancer agents. <i>Biological Procedures Online</i> , 2003, 5, 204-210.	2.9	21
38	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	5.5	21
39	FAK silencing inhibits leukemogenesis in BCR/ABL ϵ -transformed hematopoietic cells. <i>American Journal of Hematology</i> , 2009, 84, 273-278.	4.1	20
40	Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1162-1178.	2.8	20
41	Inflammatory myofibroblastic tumors associated with the placenta: a series of 9 cases. <i>Human Pathology</i> , 2020, 106, 62-73.	2.0	19
42	Metastatic Breast Cancer With <i>ESR1</i> Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. <i>Oncologist</i> , 2016, 21, 1035-1040.	3.7	18
43	Diagnostic workup of acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 317-321.	4.1	18
44	Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. <i>Oncologist</i> , 2019, 24, 1356-1367.	3.7	18
45	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	17
46	Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Surgical Pathology Clinics</i> , 2016, 9, 143-163.	1.7	14
47	Artificial Intelligence Approach for Variant Reporting. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	2.1	13
48	Clinical Grade ϵ -SNAPSHOT ϵ -Genetic Mutation Profiling in Multiple Myeloma. <i>EBioMedicine</i> , 2015, 2, 71-73.	6.1	12
49	Case 5-2017. <i>New England Journal of Medicine</i> , 2017, 376, 684-692.	27.0	11
50	A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 445-448.	5.2	11
51	Nanopore Flongle Sequencing as a Rapid, Single-Specimen Clinical Test for Fusion Detection. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 630-636.	2.8	11
52	Feasibility of Perioperative Micro ϵ -Computed Tomography of Human Lung Cancer Specimens: A Pilot Study. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 319-325.	2.5	10
53	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. <i>Blood</i> , 2021, 138, 2435-2440.	1.4	10
54	Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay. <i>American Journal of Clinical Pathology</i> , 2021, 155, 748-754.	0.7	9

#	ARTICLE	IF	CITATIONS
55	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. <i>Blood</i> , 2022, 140, 1822-1826.	1.4	8
56	Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. <i>New England Journal of Medicine</i> , 2019, 381, 1951-1960.	27.0	7
57	Predictive "biomarker piggybacking"™: an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry. <i>Histopathology</i> , 2021, 79, 260-264.	2.9	7
58	N-terminus DUX4 immunohistochemistry is a reliable methodology for the diagnosis of DUX4-fused B-lymphoblastic leukemia/lymphoma (N-terminus DUX4 IHC for) Tj ET 0.0 0.0 rBT /Overlo	2.9	7
59	Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. <i>Oncologist</i> , 2021, 26, 919-924.	3.7	6
60	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	1.4	6
61	Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 4236-4240.	5.2	6
62	Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. <i>American Journal of Hematology</i> , 2015, 90, 529-533.	4.1	5
63	Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. <i>Skeletal Radiology</i> , 2022, 51, 17-30.	2.0	5
64	Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. <i>American Journal of Hematology</i> , 2021, 96, E420-E423.	4.1	5
65	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827.	5.2	5
66	Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. <i>Oncologist</i> , 2022, 27, 82-86.	3.7	5
67	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1946-1953.	27.0	4
68	Case 10-2020: An 83-Year-Old Man with Pancytopenia and Acute Renal Failure. <i>New England Journal of Medicine</i> , 2020, 382, 1258-1266.	27.0	4
69	Premalignant Clonal Hematopoietic Proliferations. <i>American Journal of Clinical Pathology</i> , 2019, 152, 347-358.	0.7	3
70	Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. <i>Leukemia</i> , 2020, 34, 3050-3054.	7.2	3
71	Next-Generation Sequencing Somatic and Germline Assay Troubleshooting Guide Derived From Proficiency Testing Data. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 451-461.	2.5	3
72	MET Amplification in Esophageal Squamous Carcinoma. <i>International Journal of Surgical Pathology</i> , 2018, 26, 731-732.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling. <i>Blood</i> , 2016, 128, 457-457.	1.4	2
74	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5502.	3.7	2
75	BCR-ABL Kinase Dynamics and Drug Resistance.. <i>Blood</i> , 2005, 106, 1996-1996.	1.4	1
76	Peptides Derived From Mutated BCR-ABL Elicit T Cell Immunity In CML Patients. <i>Blood</i> , 2010, 116, 887-887.	1.4	1
77	Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas. <i>Blood</i> , 2021, 138, 398-398.	1.4	1
78	Rare Inherited Defects of the Complement System in Purpura Fulminans. <i>Blood</i> , 2020, 136, 35-36.	1.4	1
79	Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, , .	5.0	1
80	Rare case of leptomeningeal small lymphocytic lymphoma with <i>TP53</i> mutation detected by deep next-generation sequencing. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	1.3	1
81	Case 37-2019: A 20-Month-Old Boy with Severe Anemia. <i>New England Journal of Medicine</i> , 2019, 381, 2158-2167.	27.0	0
82	Two In Cis Variantsâ€”Two Worlds Apart. <i>Oncologist</i> , 2021, 26, 997-999.	3.7	0
83	Bone Marrow Adipocytes: A Novel Negative Regulator of the Hematopoietic Microenvironment.. <i>Blood</i> , 2007, 110, 1405-1405.	1.4	0
84	A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15124-e15124.	1.6	0
85	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. <i>Blood</i> , 2018, 132, 1491-1491.	1.4	0
86	Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program. <i>Blood</i> , 2019, 134, 5371-5371.	1.4	0
87	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020, 136, 14-14.	1.4	0
88	An unusual lymphoma involving the <i>GI</i> tract and bone marrow. <i>American Journal of Hematology</i> , 2022, 97, 1268-1269.	4.1	0